JINLING PHARM.: The holding subsidiary has received approval for the listing of potassium sulfate

JINLING PHARM. announced that its holding subsidiary Chizhou Dongsheng Pharmaceutical Co., Ltd. recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, approving the registration of potassium sulfate. Potassium sulfate is one of the raw materials for the concentrated solution of magnesium sodium potassium sulfate for oral use, suitable for bowel cleansing before any procedures requiring bowel preparation in adults. This approval indicates that the raw material meets domestic drug registration requirements and can be produced and sold in the domestic market, which is beneficial for enriching the company's raw material product line. However, due to the time required for production and sales, it will not have a significant impact on the company's current performance